Automating Neurology Peer-to-Peer Scheduling for Complex Cases

Klivira streamlines neurology peer-to-peer scheduling, transforming a high-friction process into an automated workflow for critical treatments like MS DMTs, CGRP migraine biologics, and advanced Alzheimer's therapeutics. Our platform integrates directly with clinician calendars and payer systems to expedite post-denial reviews.

For revenue cycle directors and prior authorization coordinators in neurology, managing peer-to-peer (P2P) reviews after a denial is a significant operational challenge. The manual process of reconciling clinician availability with payer medical director schedules, often for high-cost, time-sensitive neurology drugs, consumes valuable staff and clinician time. Klivira addresses these bottlenecks by automating key stages of the P2P workflow, ensuring timely patient access to essential neurological care.

The Challenge of Manual Neurology P2P Scheduling

Neurology prior authorizations frequently involve complex, high-value medications and procedures, making P2P reviews a common necessity. Denials often arise from step therapy requirements for MS disease-modifying therapies (DMTs) like ocrelizumab or ozanimod, specific documentation for Alzheimer's anti-amyloid antibodies such as lecanemab, or criteria for CGRP migraine prevention biologics. Manually coordinating these P2P calls creates significant friction, leading to missed windows, clinician burnout, and delayed patient access.

Common Neurology PA Triggers Leading to P2P Reviews

MS disease-modifying therapies (DMTs) requiring step therapy compliance or specific McDonald criteria documentation.
CGRP migraine prevention biologics (e.g., erenumab, fremanezumab) often denied for lack of prior oral preventive trials.
Alzheimer's anti-amyloid antibodies (e.g., lecanemab, donanemab) necessitating amyloid confirmation, MRI screening, and ApoE genotyping.
Advanced MRI imaging (brain MRI, MR angiography) for diagnostics or ongoing monitoring of neurological conditions.
Botox for chronic migraine, spasticity, or dystonia, frequently requiring documentation of prior therapy failures.
Spinal muscular atrophy and ALS treatments (e.g., nusinersen, risdiplam) with substantial PA and documentation requirements.

Klivira's Automated P2P Scheduling for Neurology

Klivira’s platform intelligently triages P2P-eligible denials, such as those related to clinical necessity disagreements for specific neurology drugs or advanced imaging. Our system then automates the scheduling process by integrating with clinician calendars (via FHIR Appointment resource or integrated systems like Outlook/Google) and ingesting payer-provided availability windows. This eliminates the manual back-and-forth, finding optimal, mutually available times for the ordering neurologist and the payer's medical director.

Streamlined Pre-Call Preparation and Outcome Capture

Before the P2P call, Klivira automatically assembles a comprehensive clinical packet tailored to the specific neurology case. This includes relevant EMR data (e.g., McDonald criteria for MS, EDSS scores, amyloid confirmation results, headache diaries, MRI findings), prior-line therapy history, and supporting peer-reviewed literature for off-label indications. Post-call, the platform facilitates structured outcome capture via a clinician-facing form, writing back results to the EMR as FHIR DocumentReference and Communication resources, and triggering subsequent workflows like appeal escalation or approval write-back.

Reducing Clinician Burden and Expediting Patient Care

Manual peer-to-peer reviews contribute significantly to clinician burnout, as highlighted by AMA surveys. By automating scheduling, documentation assembly, and outcome tracking, Klivira reduces the administrative load on neurologists and PA coordinators. This efficiency translates to faster resolution of denials, improved patient access to critical neurological therapies, and better utilization of clinical resources, ultimately enhancing overall practice satisfaction and care delivery.

Frequently asked questions

How does Klivira integrate with EMRs for neurology P2P scheduling?

Klivira integrates with EMRs using SMART on FHIR standards, leveraging the FHIR Appointment resource for seamless calendar synchronization with neurologists' schedules. This allows for automated discovery of available time slots and booking of P2P calls without manual intervention, directly from the clinician's existing calendar system.

What specific neurology documentation does Klivira compile for P2P calls?

For neurology P2P calls, Klivira’s automated documentation discovery pulls critical data points such as MS diagnosis (McDonald criteria), EDSS scores, MRI findings, amyloid confirmation results (PET or CSF), APOE genotype, headache diaries, and prior therapy trials. This ensures neurologists have a complete, pre-assembled clinical packet aligned with AAN Practice Guidelines.

Can Klivira handle re-authorization P2P for chronic neurology treatments?

Yes, Klivira's platform is designed to manage periodic re-authorization workflows, including P2P reviews for chronic neurology treatments like MS DMTs or Botox for chronic migraine. The system tracks re-authorization dates, auto-detects P2P-eligible denials, and initiates the automated scheduling and documentation process for ongoing care.

What types of neurology denials are most effectively addressed by Klivira's P2P automation?

Klivira's P2P automation is particularly effective for neurology denials based on clinical necessity disagreements, step therapy requirements, or specific documentation gaps. This includes denials for high-efficacy MS DMTs, CGRP migraine biologics, Alzheimer's anti-amyloid therapies, and advanced imaging, where a direct clinical discussion can often overturn the initial denial.

Does Klivira provide analytics on neurology P2P outcomes?

Yes, Klivira captures P2P outcomes and provides analytics on success patterns by denial reason, payer, and clinician. This feedback loop helps neurology practices identify common denial trends and refine their upstream prior authorization submission processes to improve initial approval rates and reduce the need for future P2P interventions.